By otakuyassine3@gmail.com 
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $60.53 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.03. The firm had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The firm’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.27) EPS. On average, analysts expect SpringWorks Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
SpringWorks Therapeutics Stock Performance
SpringWorks Therapeutics stock opened at $57.43 on Friday. The company has a market cap of $4.27 billion, a PE ratio of -14.80 and a beta of 0.81. The business’s 50-day simple moving average is $39.03 and its two-hundred day simple moving average is $36.71. SpringWorks Therapeutics has a fifty-two week low of $28.21 and a fifty-two week high of $60.00.
Insider Activity
In related news, COO Badreddin Edris sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the completion of the transaction, the chief operating officer now owns 209,600 shares in the company, valued at $8,796,912. The trade was a 8.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $54.46, for a total value of $9,530,500.00. Following the sale, the director now directly owns 130,944 shares in the company, valued at $7,131,210.24. The trade was a 57.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 302,750 shares of company stock valued at $16,139,410 in the last ninety days. Company insiders own 7.61% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a report on Monday, February 10th. HC Wainwright restated a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Wednesday. Guggenheim reduced their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Evercore ISI raised their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, SpringWorks Therapeutics currently has an average rating of “Buy” and an average target price of $70.83.
Read Our Latest Stock Report on SWTX
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Read More
Receive News & Ratings for SpringWorks Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SpringWorks Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.